January 11, 2019
The Ministry of Health, Labor and Welfare (MHLW) on January 10 ordered adverse reaction-related label revisions to a batch of drugs including Pfizer’s cancer drug Inlyta (axitinib) and Biogen Japan’s spinal muscular atrophy (SMA) treatment Spinraza (nusinersen). The MHLW urged...read more